Betta Pharmaceuticals Co., Ltd. (SHE:300558)
China · Delayed Price · Currency is CNY 50.48
-0.07 (-0.14%)
Aug 31, 2026, 3:04 PM CST
Betta Pharmaceuticals Revenue
Betta Pharmaceuticals had revenue of 936.09M CNY in the quarter ending June 30, 2026, with 15.02% growth. This brings the company's revenue in the last twelve months to 3.85B, up 23.42% year-over-year. In the year 2025, Betta Pharmaceuticals had annual revenue of 3.61B with 24.81% growth.
Revenue (ttm)
3.85B
Revenue Growth
+23.42%
P/S Ratio
5.52
Revenue / Employee
2.16M
Employees
1,785
Market Cap
21.27B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.61B | 717.39M | 24.81% |
| Dec 31, 2024 | 2.89B | 435.75M | 17.74% |
| Dec 31, 2023 | 2.46B | 79.57M | 3.35% |
| Dec 31, 2022 | 2.38B | 130.77M | 5.82% |
| Jan 1, 2022 | 2.25B | 375.59M | 20.08% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Harbin Pharmaceutical Group | 16.14B |
| Livzon Pharmaceutical Group | 10.75B |
| Tasly Pharmaceutical Group | 8.15B |
| Jiangsu Nhwa Pharmaceutical Co., LTD | 6.12B |
| Hubei Jumpcan Pharmaceutical | 5.80B |
| Kangmei Pharmaceutical | 4.97B |
| Shanghai Haoyuan Chemexpress | 3.21B |
| Jilin Aodong Pharmaceutical Group | 2.24B |
Betta Pharmaceuticals News
- 11 months ago - Chinese healthcare, biotech firms flock to Hong Kong for IPOs - South China Morning Post